Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users

Next Previous
Trial Profile

A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorcaserin (Primary) ; Ketamine; Zolpidem
  • Indications Obesity
  • Focus Pharmacodynamics
  • Sponsors Arena Pharmaceuticals; Eisai Inc

Most Recent Events

  • 20 Mar 2010 Results have been presented at the 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
  • 10 Dec 2009 Positive data has been reported at the 48th Annual Meeting of the American College of Neuropsychopharmacology, according to an Arena Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top